Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children
- 1 January 1999
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 18 (1), 42-48
- https://doi.org/10.1097/00006454-199901000-00011
Abstract
To compare the reactogenicity and immunogenicity of a novel live attenuated measles-mumps-rubella vaccine, SB MMR (Priorix; SmithKline Beecham Biologicals), with a widely used MMR vaccine, Merck MMR (M-M-R II; Merck & Co. Inc). A total of 4702 healthy children, ages 9 to 24 months, were enrolled in 8 single blind, randomized, controlled trials. Reactogenicity (local and general solicited symptoms and all unsolicited symptoms) was assessed for up to 42 days postvaccination. Immunogenicity [seroconversion rates and geometric mean titers (GMT)] was assessed at 42 or 60 days postvaccination in 1912 subjects in 7 studies. In two studies the persistence of the antibodies at Month 12 postvaccination was assessed in 201 subjects. Local symptoms (pain on or immediately after injection; pain, redness and swelling within 4 days of injection) were reported less frequently after SB MMR than Merck MMR (P 39.5°C was reported after 9.5 and 11.9% of the SB MMR and Merck MMR doses, respectively. At Days 42 to 60 postvaccination seroconversion rates for antimeasles antibodies were higher with SB MMR than with Merck MMR (98.7% vs. 96.9%, P P When administered as primary vaccination in children in the second year of life, the new SB MMR vaccine has been shown to be superior to a comparator vaccine in terms of local reactogenicity, with equivalent immunogenicity.Keywords
This publication has 29 references indexed in Scilit:
- Adverse events associated with MMR vaccines in JapanPediatrics International, 1996
- Complications of mumps vaccinesReviews in Medical Virology, 1995
- Serologic status and measles attack rates among vaccinated and unvaccinated children in rural SenegalThe Pediatric Infectious Disease Journal, 1995
- The Jeryl Lynn Vaccine Strain of Mumps Virus is a Mixture of Two Distinct IsolatesJournal of General Virology, 1993
- Pain and measles, mumps, and rubella vaccination.Archives of Disease in Childhood, 1991
- Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virusBiologicals, 1990
- Long-term antibody response after measles vaccination in an isolated arctic society in GreenlandVaccine, 1986
- Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience.BMJ, 1983
- Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studiesPublished by American Medical Association (AMA) ,1971
- Studies on immunity to measlesThe Journal of Pediatrics, 1965